Results 71 to 80 of about 2,492,664 (191)

Flow cytometry‐based monitoring of chimeric antigen receptor (CAR) T cells: Reagent selection, assay design, and clinical utility

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract Accurate quantification of chimeric antigen receptor (CAR) T cells is essential for monitoring post‐infusion CART expansion and persistence and for real‐time clinical decision‐making. Multiparameter flow cytometry (MFC) enables rapid, live‐cell detection with absolute quantification and concurrent immunophenotypic characterization. This review
Jianhua Ling, Wei Wang, Sa A. Wang
wiley   +1 more source

Extended routine lymphocyte immunophenotyping refines individual immune organization across a heterogeneous patient cohort

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract Routine TBNK immunophenotyping detects the major lymphocyte compartments but may underestimate the biologically relevant variation contributed by less frequent but well‐defined minor lymphocyte subsets. This study evaluated whether extending routine TBNK immunophenotyping with minor lymphocyte subsets provides complementary, analytically ...
Carlos Agustin Villegas Valverde, Yendry Ventura Carmenate, Vianed Marsan Suarez, Yandy Marx Castillo Aleman, Imilla Casado Hernandez, Rachely Hernandez Corrales   +5 more
wiley   +1 more source

The clinical development of obinutuzumab for the treatment of follicular lymphoma

Cancer Management and Research, 2017
Barbara Ma,1 Chaitra Ujjani2 1Department of Medicine, 2Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital, Washington, DC, USA Abstract: Impressive progress has been made in recent decades for advanced-stage follicular lymphoma ...
Ma B, Ujjani C
doaj  

Disseminated Ureaplasma urealyticum infection presenting as systemic inflammatory syndrome in ocrelizumab-treated patients with multiple sclerosis: a case series

Journal of Medical Case Reports
Background Ocrelizumab, an anti-CD20 monoclonal antibody, is widely used to treat multiple sclerosis (MS), inducing profound B-cell depletion and disease remission. However, it may rarely lead to opportunistic infections.
Anna Witkowska, Fionnuala Cahill, Killian O’Rourke, Padraig McGettrick, Tomás Burke, Geraldine McCarthy, Joanne Kitchen, Abdalla Abuelmagd, John Stack   +8 more
doaj   +1 more source

The primate EAE model points at EBV-infected B cells as a preferential therapy target in multiple sclerosis

Frontiers in Immunology, 2013
The remarkable clinical efficacy of anti-CD20 monoclonal antibodies (mAb) in relapsing-remitting multiple sclerosis (RRMS) points at the critical involvement of B cells in the disease.
Bert A 'T Hart, Sunil Anwar Jagessar, Krista eHaanstra, Ernst eVerschoor, Jon eLaman, Yolanda eKap   +5 more
doaj   +1 more source

The anti-CD20 monoclonal antibody rituximab to treat acquired haemophilia A.

Blood transfusion = Trasfusione del sangue, 2015
Acquired haemophilia A (AHA) is a rare bleeding disorder caused by the development of specific autoantibodies against naturally occurring factor VIII (FVIII). Although about half of cases are idiopathic, AHA may be associated with several non-neoplastic conditions, autoimmune disorders, as well as haematological malignancies, such as chronic ...
D'Arena, G, Grandone, E, DI MINNO, MATTEO, Musto, P, DI MINNO, GIOVANNI   +4 more
openaire   +4 more sources

Analysis of Carbohydrates and Glycoconjugates by Matrix‐Assisted Laser Desorption/Ionization Mass Spectrometry: An Update for 2023–2024

Mass Spectrometry Reviews, EarlyView.
ABSTRACT The use of MALDI mass spectrometry for the analysis of carbohydrates and glycoconjugates is a well‐established technique and this comprehensive review is the twelfth update of the original article published in 1999 and brings coverage of the literature to the end of 2024.
David J. Harvey
wiley   +1 more source

Characterization of a Novel Humanized Anti-CD20 Antibody with Potent Anti-Tumor Activity against Non-Hodgkin's Lymphoma

Cellular Physiology and Biochemistry, 2013
Background: Rituximab, a mouse Fab and human Fc chimeric antibody, has been widely used to treat Non-Hodgkin's lymphoma (NHL). However, only 48% of patients respond to the treatment and complete response rate is below 10%.
Haifeng Zhang, Liping Song, Hongtu Ye, Lide Hu, Wenlu Liang, Datao Liu   +5 more
doaj   +1 more source

Effectiveness and safety of efgartigimod in patients with anti‐NMDAR or anti‐LGI1 encephalitis and its 18F‐DPA714 PET imaging evaluation: A multicenter, single‐arm, prospective, observational real‐world study

Neuroprotection, EarlyView.
Abstract Background Efgartigimod disrupts the recycling of pathogenic IgG autoantibodies and may represent a candidate therapy for autoimmune encephalitis. This real‐world study evaluated the clinical efficacy, safety, and impact of efgartigimod on brain inflammation.
Huanyu Meng, Siqi Tu, Yifan Zhou, Ruinan Shen, Xiaoyu Chen, Zhaozhao Cheng, Limei Wang, Yan Wu, Jie Lu, Shengjun Wang, Yan Xu, Wanhui Lin, Sheng Chen   +12 more
wiley   +1 more source

Rituximab, an Anti-CD20 Monoclonal Antibody: History and Mechanism of Action [PDF]

American Journal of Transplantation, 2006
Rituximab, chimeric anti-human CD20, is approved for treatment of B-cell lymphoma in adults. It is being used experimentally in other various immune-related diseases such as immune thrombocytopenic purpura, systemic lupus erythematosus, myasthenia gravis and rheumatoid arthritis.
openaire   +2 more sources